Risk Factors Update Summary

• The company generated net product sales of $24.4 million for FYARRO in 2023, compared to $15.2 million in 2022.
• Increased costs and efforts to comply with evolving laws and regulations may be costly. This could materially affect business operations.
• The company had cash, cash equivalents, and short-term investments of $108.6 million as of December 31, 2023, compared to $172 million as of December 31, 2022.
• The company announced results from an interim analysis on the first third of participants in the PRECISION1 trial, with the trial expected to be completed by the end of 2024.
• Negotiating an extension to the Fresenius Agreement effective through March 31, 2024, with ongoing dependency on a single-source supplier.
• The company incurred net losses of $65.8 million for the year ended December 31, 2023, compared to $60.5 million for the year ended December 31, 2022.
• The company entered into a collaboration and supply agreement in October 2022 for the combination of Mirati's adagrasib and FYARRO in KRAS G12C mutant NSCLC and other solid tumors.
• Federal NOL carryforwards increased from $167 million to $187 million, with state NOL carryforwards increasing from $72 million to $92 million.
• The company had an accumulated deficit of $269.0 million as of December 31, 2023, compared to $203.2 million as of December 31, 2022.
• The company incurred net losses of $110.1 million for the year ended December 31, 2021, compared to $60.5 million for the year ended December 31, 2022.
• Leadership transitions occurred, with David Lennon appointed as President and CEO effective October 2, 2023.
• Market closing price for common stock ranged from a low of $1 to a high of $33.00 per share.
• Cash, cash equivalents, and short-term investments decreased from $172 million to $108 million.
• The company is a smaller reporting company with specific criteria related to market value, revenue, and public float.